TORONTO, ON--(Marketwired - Mar 19, 2014) - Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical and nutritional supplements company, is pleased to announce through its wholly-owned subsidiary, AllStar Health Brands Inc., that the TapouT line of Pain Relief and Muscle Growth products have been approved for sale in exchanges world-wide by a branch of the US active military and their families as well as retirees.
"This is the culmination of more than a year's hard work and we are extremely grateful to Acosta, one of the largest US distributors for making this happen," stated Dr. Daniel Bagi, President of Axxess Pharma. "The Army and Air Force (AAFES) have 2,817 facilities in 30 countries, all fifty states and five US territories. These worldwide facilities include embassies and small bases where we have troops stationed-like in Sarajevo. Retail sales in their stores last year reached $9.2 Billion."
AllStar Health Brands expects TapouT products to be well-received on military bases as the TapouT brand is popular with military personnel who embrace the toughness and dedication the brand represents.
About TapouT: TapouT is a lifestyle brand that has been at the forefront of Mixed Martial Arts since its inception in 1997. The label is rapidly growing into other sports and categories, offering merchandise for men, women and kids. TapouT has endorsed high-profile professional athletes who compete in sports such as basketball, football, baseball, stock car racing, and most famously, MMA. TapouT is sold in sporting goods stores, specialty retailers and online. For updates and more information, please visit TapouT.com.
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain to optimal health management through improved nutritional supplements.
For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.
Safe Harbor Statement:
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.